Thymosin Alpha-1 / Thymalin Blend
Status
Approved elsewhere. No FDA-approved labeling exists for either component in the United States. Thymosin alpha-1 is approved in several other countries; thymalin is registered in Russia.
What it is
A community immune blend pairing two thymus-derived preparations.
What published research measured
Combines synthetic thymosin alpha-1 with the calf thymus extract thymalin. Thymosin alpha-1 is the better-evidenced of the two by a wide margin: it is an approved medicine in a number of countries for hepatitis B and as a vaccine adjuvant, with a real randomized literature, and it was studied during the COVID-19 pandemic. Thymalin's data is Russian observational work on a tissue extract, described in its own entry. Combining a defined synthetic peptide with an undefined animal tissue extract compounds the standardization problem, because one component's composition is not fully characterized to begin with. No blend in this category has been studied as a blend. Trial evidence, where it exists, was generated on single agents given alone; no published study of the combination for interaction, additive adverse effects or altered pharmacokinetics was identified in the sources reviewed for this entry. Two practical consequences follow. A multi-compound vial is a compounded preparation, so the stability of each component in the presence of the others, and over the life of the vial, is generally unstudied. If a reaction occurs, multiple components make it difficult to attribute it to one of them, which is one reason clinical pharmacology usually introduces agents one at a time.
Source
Not tied to a single designated source; see the published research on this molecule
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.